Hormonal
Men have a higher prevalence of type 2 diabetes than women, particularly in middle-aged populations, due to greater visceral adiposity, ectopic fat accumulation, and lower insulin sensitivity.
Men are biologically more susceptible to type 2 diabetes than women, especially between ages 35 and 69. This is largely due to storing fat around the organs (visceral fat) rather than under the skin. Men should prioritize regular screening for blood sugar and insulin resistance, as their bodies are less forgiving of poor metabolic health than women's.
In most parts of the world, diabetes is more prevalent in men than in women, especially in middle-aged populations. In line with this, considering almost all animal models, males are more likely to develop obesity, insulin resistance and hyperglycaemia than females in response to nutritional challenges.
Why this rating
Supported by large-scale population studies (NCD Risk Factor Collaboration, DECODE, Inter99).
Source
Sex differences in metabolic regulation and diabetes susceptibility
Blandine Tramunt et al. · Diabetologia · 2019
DOI 10.1007/s00125-019-05040-3
More from this paper
- Endogenous oestrogens protect premenopausal women from type 2 diabetes by promoting subcutaneous fat storage, enhancing insulin sensitivity, and preserving beta-cell function, whereas the loss of oestrogen during menopause eliminates this protection and increases diabetes risk.Good
- Oestrogen receptor alpha (ERα) activation mediates the protective effects of oestrogens on metabolic health by promoting insulin synthesis, beta-cell survival, and energy expenditure through brown adipose tissue beiging.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →